Literature DB >> 23415633

PPARγ activation blocks development and reduces established neuropathic pain in rats.

J Morgenweck1, R B Griggs, R R Donahue, J E Zadina, B K Taylor.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new pharmacotherapeutic target for chronic pain. When oral (3-30 mg/kg/day in chow for 7 wk) or twice-daily intraperitoneal (1-10 mg/kg/day for 2 wk) administration began before spared nerve injury (SNI), pioglitazone, a PPARγ agonist, dose-dependently prevented multiple behavioral signs of somatosensory hypersensitivity. The highest dose of intraperitoneal pioglitazone did not produce ataxia or reductions in transient mechanical and heat nociception, indicating that inhibitory effects on hypersensitivity were not secondary to adverse drug-induced behaviors or antinociception. Inhibitory effects on hypersensitivity persisted at least one week beyond cessation of pioglitazone administration, suggestive of long-lasting effects on gene expression. Blockade of PPARγ with GW9662, an irreversible and selective PPARγ antagonist, dose-dependently reduced the inhibitory effect of pioglitazone on hypersensitivity, indicating a PPARγ-dependent action. Remarkably, a single preemptive injection of pioglitazone 15 min before SNI attenuated hypersensitivity for at least 2 weeks; this was enhanced with a second injection delivered 12 h after SNI. Pioglitazone injections beginning after SNI also reduced hypersensitivity, albeit to a lesser degree than preemptive treatment. Intraperitoneal pioglitazone significantly reduced the nerve injury-induced up-regulation of cd11b, GFAP, and p-p38 in the dorsal horn, indicating a mechanism of action involving spinal microglia and/or astrocyte activation. Oral pioglitazone significantly reduced touch stimulus-evoked phospho-extracellular signal-related kinase (p-ERK) in lamina I-II, indicating a mechanism of action involving inhibition of central sensitization. We conclude that pioglitazone reduces spinal glial and stimulus-evoked p-ERK activation and that PPARγ activation blocks the development of and reduces established neuropathic pain.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23415633      PMCID: PMC3695821          DOI: 10.1016/j.neuropharm.2013.01.020

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  54 in total

1.  Enhancement of stimulation-induced ERK activation in the spinal dorsal horn and gracile nucleus neurons in rats with peripheral nerve injury.

Authors:  Hu Wang; Yi Dai; Tetsuo Fukuoka; Hiroki Yamanaka; Koichi Obata; Atsushi Tokunaga; Koichi Noguchi
Journal:  Eur J Neurosci       Date:  2004-02       Impact factor: 3.386

2.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

Authors:  Michael T Heneka; Magdalena Sastre; Lucia Dumitrescu-Ozimek; Anne Hanke; Ilse Dewachter; Cuno Kuiperi; Kerry O'Banion; Thomas Klockgether; Fred Van Leuven; Gary E Landreth
Journal:  Brain       Date:  2005-04-07       Impact factor: 13.501

Review 3.  Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

Authors:  D L Feinstein; A Spagnolo; C Akar; G Weinberg; P Murphy; V Gavrilyuk; C Dello Russo
Journal:  Biochem Pharmacol       Date:  2005-07-15       Impact factor: 5.858

Review 4.  Pathophysiologic mechanisms of neuropathic pain.

Authors:  B K Taylor
Journal:  Curr Pain Headache Rep       Date:  2001-04

5.  JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats.

Authors:  Makoto Tsuda; Yuta Kohro; Takayuki Yano; Tomoko Tsujikawa; Junko Kitano; Hidetoshi Tozaki-Saitoh; Satoru Koyanagi; Shigehiro Ohdo; Ru-Rong Ji; Michael W Salter; Kazuhide Inoue
Journal:  Brain       Date:  2011-03-02       Impact factor: 13.501

6.  Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen.

Authors:  Antonietta Bernardo; Maria Antonietta Ajmone-Cat; Laura Gasparini; Ennio Ongini; Luisa Minghetti
Journal:  J Neurochem       Date:  2005-02       Impact factor: 5.372

7.  Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions.

Authors:  A Bernardo; G Levi; L Minghetti
Journal:  Eur J Neurosci       Date:  2000-07       Impact factor: 3.386

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

Review 9.  Pathological and protective roles of glia in chronic pain.

Authors:  Erin D Milligan; Linda R Watkins
Journal:  Nat Rev Neurosci       Date:  2009-01       Impact factor: 34.870

10.  Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury.

Authors:  Takehiko Maeda; Norikazu Kiguchi; Yuka Kobayashi; Masanobu Ozaki; Shiroh Kishioka
Journal:  J Pharmacol Sci       Date:  2008-11-13       Impact factor: 3.337

View more
  36 in total

Review 1.  Regulatory mechanisms and therapeutic potential of microglial inhibitors in neuropathic pain and morphine tolerance.

Authors:  Er-Rong Du; Rong-Ping Fan; Li-Lou Rong; Zhen Xie; Chang-Shui Xu
Journal:  J Zhejiang Univ Sci B       Date:  2020 Mar.       Impact factor: 3.066

2.  Analgesic tolerance to morphine is regulated by PPARγ.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Giulia Scuppa; Serena Stopponi; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Phosphorylated neuronal nitric oxide synthase in neuropathic pain in rats.

Authors:  Zhidong Zhou; Yingping Liang; Fumou Deng; Yong Cheng; Jing Sun; Lian Guo; Guohai Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Deep in the brain: Changes in subcortical function immediately preceding a migraine attack.

Authors:  Noemi Meylakh; Kasia K Marciszewski; Flavia Di Pietro; Vaughan G Macefield; Paul M Macey; Luke A Henderson
Journal:  Hum Brain Mapp       Date:  2018-03-02       Impact factor: 5.038

5.  CYP2J2 attenuates metabolic dysfunction in diabetic mice by reducing hepatic inflammation via the PPARγ.

Authors:  Rui Li; Xizhen Xu; Chen Chen; Yan Wang; Artiom Gruzdev; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-11-11       Impact factor: 4.310

Review 6.  PPARs and pain.

Authors:  Bright N Okine; Jessica C Gaspar; David P Finn
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

7.  Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.

Authors:  Ryan B Griggs; Renee R Donahue; Braxton G Adkins; Katie L Anderson; Olivier Thibault; Bradley K Taylor
Journal:  J Pain       Date:  2015-12-12       Impact factor: 5.820

8.  Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway.

Authors:  Li Zhuang; Ke Li; Gaowei Wang; Tao Shou; Chunlin Gao; Yong Mao; Mingliang Bao; Mingli Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2017-11-02

9.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

10.  Resolvin D1: A New Path to Unleash the Analgesic Potential of Peroxisome Proliferator-activated Receptor-γ for Postoperative Pain in Patients with Diabetes.

Authors:  Bradley K Taylor
Journal:  Anesthesiology       Date:  2015-12       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.